For these reasons, the MDM2–p53 interaction is a target in soft-tissue tumor therapy due to its critical role in regulating the p53 tumor suppressor pathway, which is often deregulated in the MDM2-amplified sarcoma cancers. Here, TP53 is linked to short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome.